Zandatrigine（Cat No.:I033077）is an investigational small-molecule compound that functions as a selective sodium channel blocker, primarily targeting the Nav1.7 channel subtype. Nav1.7 plays a critical role in pain signal transmission within peripheral neurons, making it a key target for non-opioid analgesic development. By inhibiting Nav1.7 activity, Zandatrigine aims to reduce chronic and neuropathic pain without the side effects associated with traditional pain medications. It is being studied for its potential in treating conditions such as diabetic neuropathy and other pain syndromes, offering a promising approach to targeted, non-addictive pain management.